Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin versus mebeverine for gastrointestinal symptoms in irritable bowel syndrome
IRCT20210115050039N1Phase 2Completed
- Sponsor
- Islamic Azad University
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in irritable bowel syndrome (IBS) comparing Rifaximin with Mebeverine (2 arms). Primary endpoints: Change in abdominal pain score, Change in bloating score and 1 more. Started May 2018; status: completed.
02
Drugs
rifaximinmebeverine
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on IRCT20210115050039N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210115050039N1.